Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Increased Uric Acid and Glucose Concentrations in Vitreous and Serum of Patients with Diabetic Macular Oedema

Krizova L.a · Kalousova M.b · Kubena A.c · Benakova H.b · Zima T.b · Kovarik Z.a · Kalvoda J.a · Kalvodova B.a

Author affiliations

aDepartment of Ophthalmology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague and bInstitute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, and cFaculty of Pharmacy, Charles University in Prague, Hradec Kralove, Czech Republic

Related Articles for ""

Ophthalmic Res 2011;46:73–79

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 23, 2010
Accepted: November 24, 2010
Published online: January 14, 2011
Issue release date: July 2011

Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 3

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE

Abstract

Background: Diabetic retinopathy (DR) is characterized by blood-retina barrier breakdown induced by local changes in the retina and systemic factors. We investigated vitreous and serum levels of glucose and uric acid (UA) in patients with DR and aimed to describe their correlation with the grade of DR. Methods: Prospective study of 81 patients with DR and 48 non-diabetic controls. Biochemical analysis of vitreous and serum samples was performed. Results: UA and glucose concentrations in vitreous and serum were significantly higher in diabetic patients than in controls. Absolute ratios (vitreous level/serum level) of UA and glucose were higher in proliferative compared with non-proliferative DR. Conclusions: The results suggest that, apart from glucose, increased levels of UA in diabetic patients may also be involved in the pathogenesis and progression of DR.

© 2011 S. Karger AG, Basel


References

  1. Sheetz MJ, King GL: Molecular understanding of hyperglycaemia’s adverse effects for diabetic complications. JAMA 2002;228:2579–2588.
    External Resources
  2. Gardner TW, Antonetti DA, Barber AJ, La Noue KF, Levison SW: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47:S253–S262.
  3. Engler C, Krogsaa B, Lund-Andersen H: Blood-retina barrier permeability and its relation to the progression of diabetic retinopathy in type 1 diabetics. Graefe’s Arch Clin Exp Ophthalmol 1991;229:442–446.
  4. Huang EJ, Kuo WW, Chen YJ, Chen TH, Chang MH, Lu MC, Tzang BS, Hsu HH, Huang CY, Lee SD: Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 2006;366:293–298.
  5. Kroll P, Büchele Rodrigues E, Hoerle S: Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica 2007;221:78–94.
  6. Aiello LP, Cahill MT, Wong JS: Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001;132:760–776.
  7. Castillo A, Del Castillo JMB, Diaz D, Sayagues O, Rubal JL, Garcia-Sanchez J: Analysis of the blood-retinal barrier: its relation to clinical and metabolic factors and progression to retinopathy in juvenile diabetics: a 4-year follow-up study. Graefe’s Arch Clin Exp Ophthalmol 1996;234:246–250.
  8. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, Fuller JH, EURODIAB Prospective Complications Study Group: Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001;44:2203–2209.
  9. Zhang L, Krzentowski G, Albert A, Lefebvre PJ: Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24:1275–1279.
  10. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801–1815.
  11. UK Prospective Diabetes Study (UKPDS) Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703–712.
  12. Chew EY: Diabetic retinopathy and lipid abnormalities. Curr Opin Ophthalmol 1997;8:59–62.
  13. Olivarius N, Nielsen N, Andersen A: Diabetic retinopathy in newly diagnosed middle-aged and elderly patients: prevalence and interrelationship with microalbuminuria and triglycerides. Graefe’s Arch Clin Exp Ophthalmol 2001;239:664–672.
  14. Ciulla TA, Amador AG, Zinman B: Diabetic retinopathy and diabetic macular edema: pathophysiology, screening and novel therapies. Diabetes Care 2003;26:2653–2664.
  15. Kowluru RA, Chan P-S: Oxidative stress and diabetic retinopathy. Exp Diabetes Res DOI: 10.1155/2007/43603.
    External Resources
  16. Liter LA: The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 2005;68:S3–S14.
  17. Ioachimescu AG, Brennant DM, Hoart BM, Kashyap SR, Hoogwerf BJ: Serum uric acid, mortality and glucose control in patients with type 2 diabetes mellitus: a PreCIS database study. Diabet Med 2007;24:1369–1374.
  18. Hayden MR, Tyagi SC: Uric acid – a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab DOI: 10.1186/1743-7075-1-10.
    External Resources
  19. Zoccali C, Maio R, Mallamaci F, Sesti G, Pericone F: Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006;17:1466–1471.
  20. García-Ramírez M, Canals F, Hernandéz C, Colomé N, Ferrer C, Carrasco E, García-Arumí J, Simó R: Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007;50:1249–1303.
  21. WHO Study Group: Diabetes mellitus: report of a WHO study group. World Health Organ Tech Rep Ser 1985;727:1–113.
    External Resources
  22. Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report No 12. Ophthalmology 1991;98:823–33.
  23. Johnson RJ, Kang DH, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183–1190.
  24. Yokoi M, Yamagishi S-I, Takeuchi M, Ohgami K, Okamoto T, Saito W, Muramatsu M, Imazumi T, Ohno S: Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005;89:673–675.
  25. Marumo T, Noll T, Schini-Kerth VB, Harley EA, Duhault J, Piper HM, Busse R: Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor. J Vasc Res 1999;36:510–515.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 23, 2010
Accepted: November 24, 2010
Published online: January 14, 2011
Issue release date: July 2011

Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 3

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: https://www.karger.com/ORE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.